View expert perspective videos and downloadable slides from our satellite symposium at EBCC-11 in Barcelona. This activity will help to enhance your understanding of ovarian suppression in endocrine-sensitive breast cancer in order to provide optimal treatment that delivers favorable efficacy while minimizing toxicity.
Apr 10, 2018
Apr 10, 2019
Prue Francis, MDPeter MacCallum Cancer Centre
Michael Gnant, MD, FACSUniversity of Vienna
Fedro Peccatori, MD, PhDEuropean Institute of Oncology
Fertility preservation and impact of pregnancy in women with early breast cancer
Fedro Peccatori, MD, PhD
Exploiting the benefits of ovarian suppression in early breast cancer
Prue Francis, MD
Managing the downside of ovarian suppression
Michael Gnant, MD, FACS
Michael Gnant, MD, FACS
This educational activity is specifically designed for oncologists, breast surgeons, and other healthcare professionals interested in and/or involved in the treatment of breast cancer and who wish to understand some of the latest developments in endocrine treatments for young women with estrogen receptor–positive (ER+) disease.
After successful completion of this educational activity, participants should be able to:
- Describe the latest data from clinical trials of endocrine treatment for premenopausal women with early breast cancer and identify those most likely to benefit from combined endocrine therapy that includes ovarian function suppression (OFS)
- Show an awareness of the endocrine and skeletal side effects of OFS and strategies for their management
- Summarize the available options for fertility preservation for premenopausal women with early breast cancer
- Understand the impact of pregnancy on breast cancer outcomes
This educational activity is supported by Ipsen.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Francis has disclosed that she has received honoraria or consultation fees from AstraZeneca. She has also disclosed that she has received support from Pfizer for an overseas lecture. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Gnant has disclosed that he has received grants/research support from AstraZeneca, Pfizer, Novartis, and Roche. He has also received honoraria or consultation fees from Accelsiors, Amgen, AstraZeneca, Celgene, GlaxoSmithKline, Novartis, OBI-Pharma, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Peccatori has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – research support received by his institution from Amgen and Bayer
- Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
- Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.